Señales en vivo de INTI | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 15:44):

Stats
Volumen de hoy	1 250.00
Volumen promedio	9 237.00
Capitalización de mercado	14.79M
EPS	$0 ( 2024-03-29 )
Próxima fecha de ganancias	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.30
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-11	Osman Ronald E	Buy	25 000	Common Stock
2023-05-05	Ronald E Osman Irrevocable Trust Iii	Sell	0	Common Stock
2023-05-05	Tpb 2012 Llc	Buy	0	Common Stock
2023-05-05	Tpb 2012 Llc	Sell	0	Common Stock
2023-05-05	Mcnulty James A	Buy	20 101 057	Common Stock

INSIDER POWER
-57.75
Last 91 transactions
Buy: 128 793 757 \| Sell: 121 688 284

Inhibitor Therapeutics, Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Inhibitor Therapeutics, Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.0176

FY	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.0176

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$0.0325

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.000803

Financial Reports:

No articles found.

Inhibitor Therapeutics,

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.